Related Experiment Videos
[Treatment of hypertension with urapidil (Ebrantil)]
Vutreshni Bolesti
|January 1, 1986
Insights
Ebrantil effectively treats hypertension when added to existing therapies, showing significant antihypertensive effects in most patients. This study found Ebrantil to be well-tolerated with no adverse effects or changes in heart rate.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Trials
Context:
- Hypertension management
- Combination therapy in cardiovascular disease
- Open-label clinical studies
Purpose:
- To evaluate the efficacy and safety of Ebrantil as an add-on therapy for moderate to severe hypertension.
- To assess the antihypertensive effects of Ebrantil in patients already on beta-blockers and/or diuretics.
Summary:
- Ebrantil was administered to 32 patients with moderate to severe hypertension for 3 months.
- A very good antihypertensive effect was observed in 31.3% of patients, with moderate effects in 65.6%.
- Ebrantil demonstrated a favorable safety profile, with no reported adverse effects or impact on heart rate.
Impact:
- Ebrantil shows promise as a safe and effective antihypertensive agent when used in combination therapy.
- The findings support the use of Ebrantil for improving blood pressure control in difficult-to-treat hypertension.
- This study contributes to understanding Ebrantil's role in managing complex hypertensive cases.
Abstract:
Ebrantil has been added to the beta-blockers and/or diuretics in the treatment of 32 patients with moderate and severe hypertension under the conditions of 3-month open clinical experiment. A very good antihypertensive effect was obtained in 31.3% of the treated, moderate--in 65.6% and unsatisfactory--in 3.1%. Ebrantil does not change the heart rate and is, in fact, without any adverse effects.